Search

Your search keyword '"Ullah, Fauzia"' showing total 38 results
Start Over Author "Ullah, Fauzia"
38 results on '"Ullah, Fauzia"'

6. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma

Author

Lin, Cindy Hsin-Ti, primary, Tariq, Muhammad Junaid, additional, Ullah, Fauzia, additional, Sannareddy, Aishwarya, additional, Khalid, Farhan, additional, Abbas, Hasan, additional, Bader, Abbas, additional, Samaras, Christy, additional, Valent, Jason, additional, Khouri, Jack, additional, Anwer, Faiz, additional, Raza, Shahzad, additional, and Dima, Danai, additional

Published
2024
Full Text
View/download PDF

7. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.

Author

Dima, Danai, Hughes, Michael, Orland, Mark, Ullah, Fauzia, Goel, Utkarsh, Anwer, Faiz, Raza, Shahzad, Mazzoni, Sandra, Bhutani, Divaya, Williams, Louis, Lentzsch, Suzanne, Samaras, Christy, Valent, Jason, Chakraborty, Rajshekhar, and Khouri, Jack

Subjects
OVERALL survival, FAILURE (Psychology), SALVAGE therapy, TREATMENT failure, CARDIAC patients
Abstract

Background: Daratumumab's incorporation in the upfront treatment of light chain (AL) amyloidosis has led to daratumumab (dara) refractoriness early in disease course. Patients who experience relapse or have suboptimal response to dara-based-therapy, have limited options. Objective: This study aimed to evaluate the outcomes of venetoclax-based therapy in t(11;14) positive AL patients who previously failed dara. Methods: Thirty-one patients with AL were included in this bi-institutional retrospective analysis. Results: Dara failure was due to inadequate response in 20 (65%) patients, haematologic relapse in 7 (22%), and both haematologic plus organ relapse in 4 (13%). Overall haematologic response rate to venetoclax-based therapy was 97%, with ≥ VGPR being 91%. Of the 19 evaluable patients with cardiac involvement, 14 (74%) achieved organ response. Of the 13 evaluable patients with renal involvement, 6 (46%) achieved organ response. With a median follow-up of 22 months, median time-to-next-treatment (TTNT) and overall survival (OS) were not reached. The 12- and 24-month TTNT rates were 74% and 56%, respectively. At data-cut-off, four patients had died, all from AL-related organ complications. The 12- and 24-month OS rates were 89% and 85%, respectively. Grade ≥3 adverse events occurred in 26% of patients, with 6% due to infections. Conclusion: These findings are encouraging for the use of venetoclax as salvage therapy post-dara failure. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.

Author

Dima, Danai, Goel, Utkarsh, Sannareddy, Aishwarya, Ibeh, Nnaemeka, Ullah, Fauzia, Afrough, Aimaz, Mazzoni, Sandra, Mehdi, Ali, Rudoni, Joslyn, Raza, Shahzad, De Simone, Nicole, Williams, Louis, Khan, Adeel, Rashid, Aliya, Rice, Mikhaila, Ricci, Kristin, Samaras, Christy, Valent, Jason, Anderson, Larry D., and Anwer, Faiz

Subjects
PLASMA exchange (Therapeutics), TREATMENT effectiveness, MULTIPLE myeloma, IMMUNOGLOBULIN light chains, KIDNEY diseases
Abstract

Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell‐directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid reduction of the serum free light chain (sFLC). However, the role of TPE continues to remain a subject of debate. The goal of this retrospective bi‐institutional study was to evaluate the clinical outcomes of TPE in combination with systemic therapy. Eighty patients were included in this analysis, of whom 72.5% had ≥50% drop in their initial involved sFLC. At 3 months from TPE initiation, the overall hematologic response rate (ORR) was 67.5% with a very good partial response or better (≥VGPR) rate of 40%. At 6 months, ORR was 57.5%, with ≥VGPR rate of 49%. The renal response rate at 3 and 6 months was 47.5% and 43.75%, respectively; the overall renal response rate was 48.75%. On multivariable analysis, every one unit increase in baseline creatinine (odds ratio [OR] 0.76, p = 0.006), and achievement of ≥VGPR (OR 21.7 p < 0.0001) were significantly associated with renal response. Also, a ≥50% drop in sFLC was favorably associated with renal response (OR 3.39, p = 0.09). With a median follow‐up of 36.4 months, the median overall survival (OS) was 11 months. On multivariable analysis, achievement of renal response (hazard ratio [HR] 0.3, p < 0.0001) and newly diagnosed disease (NDMM; HR 0.43, p = 0.0055) were associated with improved OS. Among NDMM patients, those treated with daratumumab‐based regimens had a trend for better OS (p = 0.15), compared to other regimens, but the difference was not significant. At the end of follow‐up, an estimated 40.4% of patients who were on dialysis were able to become dialysis independent. In conclusion, our study highlights the poor survival of patients with MCN. Achievement of early renal response is crucial for prolonged OS, with daratumumab‐based therapies showing promise. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study

Author

Ahmed, Sairah, primary, Bashir, Qaiser, additional, Bassett, Roland L., additional, Ullah, Fauzia, additional, Aung, Fleur, additional, Valdez, Benigno C., additional, Alousi, Amin M., additional, Hosing, Chitra, additional, Kebriaei, Partow, additional, Khouri, Issa, additional, Marin, David, additional, Nieto, Yago, additional, Olson, Amanda, additional, Oran, Betul, additional, Qazilbash, Muzaffar H., additional, Rezvani, Katayoun, additional, Mehta, Rohtesh, additional, Shpall, Elizabeth J., additional, Ciurea, Stefan, additional, Andersson, Borje S., additional, Champlin, Richard E., additional, and Popat, Uday R., additional

Published
2024
Full Text
View/download PDF

11. Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies.

Author

Dima, Danai, Lopetegui‐Lia, Nerea, Ogbue, Olisaemeka, Osantowski, Bennett, Ullah, Fauzia, Jia, Xuefei, Song, Jung Min, Gastman, Brian, Isaacs, James, Kennedy, Lucy Boyce, and Funchain, Pauline

Subjects
MELANOMA, ADVERSE health care events, OVERALL survival, DISEASE relapse, SURVIVAL rate
Abstract

Background: Both immunotherapy (IO) and targeted therapy (TT) are used as adjuvant (adj) treatment for stage III melanoma, however, data describing real‐world outcomes are limited. In addition, a significant proportion of patients relapse, for whom best management is unclear. The aim of our study was to assess the efficacy, and safety of adj anti‐PD1 IO and TT in a real‐world cohort of patients with resected stage III melanoma, and further delineate patterns of recurrence and treatment strategies. Methods: We retrospectively analyzed 130 patients who received adj therapy (100 anti‐PD1 IO and 30 TT). Results: At a median follow‐up of 30 months, median relapse‐free survival (RFS) was 24.6 (95% CI, 17–not reached [NR]) versus 64 (95% CI, 29.5–NR) months for the TT and IO groups, respectively (p = 0.26). Median overall survival (OS) was NR for either subgroup. At data cutoff, 77% and 82% of patients in TT and IO arms were alive. A higher number of grade ≥3 treatment‐related adverse events (AEs) were noted in the IO group (11% vs. 3%), however, a higher proportion of patients permanently discontinued adj therapy in the TT group (43% vs. 11%) due to toxicity. Strategies at relapse and outcomes were variable based on location and timing of recurrence. A significant number of patients who relapsed after adj IO received a second round of IO. Among them, patients who were off adj IO at relapse had superior second median RFS (mRFS2), compared to those who relapsed while on adj IO; mRFS2 was NR versus 5.1 months (95% CI, 2.5–NR), respectively, p = 0.02. Conclusion: In summary, both TT and IO yielded prolonged RFS in a real‐world setting, however, longer follow‐up is needed to determine any potential OS benefit. Adj therapy, particularly TT, may not be as well tolerated as suggested in clinical trials, with lower completion rates (59% vs. 74%) in a real‐life setting. Overall, patients who relapse during adj therapy have poor outcomes, while patients who relapse after discontinuation of adj IO therapy appear to benefit from IO re‐treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice

Author

Dima, Danai, primary, Ullah, Fauzia, additional, Mazzoni, Sandra, additional, Williams, Louis, additional, Faiman, Beth, additional, Kurkowski, Austin, additional, Chaulagain, Chakra, additional, Raza, Shahzad, additional, Samaras, Christy, additional, Valent, Jason, additional, Khouri, Jack, additional, and Anwer, Faiz, additional

Published
2023
Full Text
View/download PDF

20. Immune Checkpoint Molecules Regulate Paroxysmal Nocturnal Hemoglobinuria Clonal Evolution

Author

Kawashima, Naomi, primary, Ponvilawan, BEN, additional, Rayman, Pat, additional, Powers, Jennifer, additional, Ullah, Fauzia, additional, Kubota, Yasuo, additional, Aly, Mai, additional, Wang, Li Lily, additional, Pagliuca, Simona, additional, Visconte, Valeria, additional, Diaz-Montero, C. Marcela, additional, Maciejewski, Jaroslaw P., additional, and Gurnari, Carmelo, additional

Published
2022
Full Text
View/download PDF

21. Dead and Deah-Box Helicases Other Than DDX41 Are Mutated in Myeloid Neoplasia

Author

Gurnari, Carmelo, primary, Durmaz, Arda, additional, Kubota, Yasuo, additional, Aly, Mai, additional, Ogbue, Olisaemeka, additional, Ullah, Fauzia, additional, Dima, Danai, additional, Awada, Hussein, additional, Kawashima, Naomi, additional, LaFramboise, Thomas, additional, Padgett, Richard A, additional, Haferlach, Torsten, additional, Maciejewski, Jaroslaw P., additional, and Visconte, Valeria, additional

Published
2022
Full Text
View/download PDF

22. Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations

Author

Awada, Hussein, primary, Durmaz, Arda, additional, Kewan, Tariq, additional, Ullah, Fauzia, additional, Dima, Danai, additional, Awada, Hassan, additional, Pagliuca, Simona, additional, Meggendorfer, Manja, additional, Haferlach, Torsten, additional, Gurnari, Carmelo, additional, Visconte, Valeria, additional, and Maciejewski, Jaroslaw P., additional

Published
2022
Full Text
View/download PDF

25. Clinico-Molecular Risk Factors and Management of Thrombosis in a Large Real-Life Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria in the New Era of Anti-Complement Inhibitors and Doacs

Author

Gurnari, Carmelo, primary, Awada, Hussein, additional, Aly, Mai, additional, Dima, Danai, additional, Ullah, Fauzia, additional, Kawashima, Naomi, additional, Kubota, Yasuo, additional, Colak, Ceylan, additional, Visconte, Valeria, additional, Pagliuca, Simona, additional, Patel, Bhumika J., additional, Bat, Taha, additional, and Maciejewski, Jaroslaw P., additional

Published
2022
Full Text
View/download PDF

26. Intense Immunosuppressive Therapy (anti-thymocyte globulin, alemtuzumab) As Salvage Therapy in Refractory T-Cell Large Granular Lymphocytic Leukemia and Pure Red Cell Aplasia

Author

Ullah, Fauzia, primary, Dima, Danai, additional, Gurnari, Carmelo, additional, Balasubramanian, Suresh Kumar, additional, Ogbue, Olisaemeka, additional, Awada, Hussein, additional, Kawashima, Naomi, additional, Omar, Najiullah, additional, Thota, Swapna, additional, Carraway, Hetty E., additional, Visconte, Valeria, additional, and Maciejewski, Jaroslaw P., additional

Published
2022
Full Text
View/download PDF

27. Multiple Myeloma Therapy: Emerging Trends and Challenges

Author

Dima, Danai, primary, Jiang, Dongxu, additional, Singh, Divya Jyoti, additional, Hasipek, Metis, additional, Shah, Haikoo S., additional, Ullah, Fauzia, additional, Khouri, Jack, additional, Maciejewski, Jaroslaw P., additional, and Jha, Babal K., additional

Published
2022
Full Text
View/download PDF

33. Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Author

Orland, Mark, Dima, Danai, Ullah, Fauzia, Awada, Hussein, Basali, Diana, Faiman, Beth M., Scott, Cynthia, Mazzoni, Sandra, Williams, Louis S., Samaras, Christy J., Valent, Jason, Anwer, Faiz, Raza, Shahzad, and Khouri, Jack

Abstract

Background:Light chain (AL) amyloidosis is a rare plasma cell disorder (PCD) characterized by misfolded light chains produced by clonal plasma cells leading to organ dysfunction. Over the past few years, the introduction of daratumumab (dara), a CD38 monoclonal antibody, into clinical practice has markedly improved outcomes, however, relapses still occur with limited available options. Venetoclax (VEN) is a BCL-2 inhibitor that has shown encouraging clinical efficacy in PCDs harboring the translocation between the chromosomes 11 and 14 (t[11;14]). The aim of this study was to evaluate the efficacy of VEN-based therapy (VBT) in patients with dara-refractory AL who were positive for t(11;14).

Published
2023
Full Text
View/download PDF

34. LGL in MGUS or MGUS in LGL? Lessons of Nature and Their Clinical Implications

Author

Bravo-Perez, Carlos, Gurnari, Carmelo, Kawashima, Naomi, Dima, Danai, Ogbue, Olisaemeka, Guarnera, Luca, Kubota, Yasuo, Williams, Nakisha D, Ahmed, Arooj, Ullah, Fauzia, Durmaz, Arda, Nakashima, Megan, Visconte, Valeria, and Maciejewski, Jaroslaw P.

Abstract

Associations between seemingly unrelated entities often reveal important lessons of nature, instructive for the understanding of mutual pathogenic roots. While investigating the clinical features of T-cell large granular lymphocytic leukemia (LGL), we noted the frequent presence of plasma cell dyscrasias/monoclonal gammopathies (MGs), chiefly MGUS. There are several potential explanations for this co-occurrence: 1) similar demographics (both conditions mostly presenting in the elderly); 2) the possibility that the two precursors originate from an initial polyclonal immune response to a common target; and 3) as alternative, that monoclonal plasma cells or the Ig product may be the targets of cytotoxic T-LGL cells in a context of tumor surveillance reaction. For instance, clonal TCR may recognize the M protein idiotype or vice versacausing aberrant activations. In addition, while MGUS should not be associated with cytopenias, responses to anti-myeloma therapies have been observed in LGL with MGUS refractory to traditional immunosuppressive therapies.

Published
2023
Full Text
View/download PDF

35. Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

Author

Ahmed, Arooj, Dima, Danai, Row, Kerri, Ullah, Fauzia, Awada, Hussein, Basali, Diana, Kurish, Heena, Rice, Mikhaila, Rudoni, Joslyn, Duco, Marissa, Faiman, Beth M., Khouri, Jack, Mazzoni, Sandra, Williams, Louis S., Raza, Shahzad, Samaras, Christy J., Valent, Jason, and Anwer, Faiz

Abstract

Introduction:Rapidly evolving therapies for multiple myeloma (MM) have drastically changed the treatment landscape over the last decade. Despite the introduction of novel agents into clinical practice, MM remains challenging to treat in the setting of aggressive relapse and/or multi-refractory disease, accompanied by high tumor burden and extramedullary sites. Intensive chemotherapy with VDT-PACE (bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide)-like regimens may be used for a limited number of cycles as a bridging regimen to quickly achieve cytoreduction. This study aimed to evaluate outcomes of patients treated with VDT-PACE-like regimens (VPRs) for relapsed-refractory MM (RRMM) at our center.

Published
2023
Full Text
View/download PDF

38. Immunotherapy for Head and Neck Squamous Cell Carcinoma: Present and Future Approaches and Challenges.

Author

Orland MD, Ullah F, Yilmaz E, and Geiger JL

Abstract

Despite significant progress and improving outcomes in the management of head and neck squamous cell carcinoma (HNSCC), there are few effective treatment options for patients with recurrent or metastatic head and neck squamous cell carcinoma. The advent of immune checkpoint inhibitors has changed the treatment algorithm of head and neck squamous cell carcinoma and are approved in the frontline setting for recurrent and metastatic (R/M) head and neck squamous cell carcinomas. Although promising for some patients, most patients with R/M HNSCC do not derive clinical benefit from currently approved checkpoint inhibitors. Many studies are underway to identify the patient population that would benefit the most from immunotherapy as well as postimmunotherapy treatment failures, including novel combinations of immunomodulatory therapies. In this review, we summarize the clinical development of all major clinical trials of immunotherapy in HNSCC.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results